Can an economist determine whether you or your loved one receives breakthrough cystic fibrosis treatments? What is the Institute for Clinical and Economic Review (ICER) and why does it have so much influence on health plan coverage policy?

Join us for a 30 minute webinar hosted by the Institute for Patient Access and the Cystic Fibrosis Engagement Network as we discuss what ICER is, how it influences health care policy and what you can do to help cystic fibrosis patients and families as ICER begins its review of the latest cystic fibrosis treatments, including Trikafta.